| Trial ID: | L6151 |
| Source ID: | NCT00237952
|
| Associated Drug: |
Edta Chelating Agents
|
| Title: |
Environmental Exposure to Lead and Progressive Renal Insufficiency in Type II Diabetic Nephropathy
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetic Nephropathies|Diabetes Mellitus, Type II
|
| Interventions: |
DRUG: EDTA chelating agents
|
| Outcome Measures: |
Primary: The primary end point is an increase in serum creatinine to 1.5 times the base-line value, measured on two occasions one month apart, or the need for hemodialysis during the longitudinal observation period. | Secondary: A secondary end point is a temporal change in the creatinine clearance or glomerular filtration rate during the follow-up period.
|
| Sponsor/Collaborators: |
Sponsor: Chang Gung Memorial Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose: TREATMENT
|
| Start Date: |
2005-08
|
| Completion Date: |
|
| Results First Posted: |
|
| Last Update Posted: |
2009-06-23
|
| Locations: |
Chang Gung Memorial Hospital, Lin-Kou Medical Center, Taipei, Taiwan, 105, China|Chang Gung Memorial Hospital, Taipei, Taiwan, 105, China
|
| URL: |
https://clinicaltrials.gov/show/NCT00237952
|
